Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
The researchers tested whether a ctDNA-guided strategy could lower the need for adjuvant chemotherapy without increasing the risk of recurrence. Recurrence-free survival at 2 years was the main efficacy end objective. Adjuvant chemotherapy usage was a significant secondary end goal.
Oncology, Medical January 9th 2023
Clinical Advances in Hematology & Oncology
ctDNA provides an intriguing, noninvasive means of evaluating solid organ malignancies—from early diagnosis to personalized treatment decisions to prognosis and estimating risk of recurrence.
Oncology, Medical July 25th 2022